Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

Core Insights - REC-3565 is a promising MALT1 inhibitor aimed at treating relapsed or refractory B-cell lymphomas, with the first patient dosed in the Phase 1 EXCELERIZE clinical study [1][2] - The drug is designed to minimize the risk of hyperbilirubinemia, a common side effect associated with other MALT1 inhibitors, enhancing its safety profile [1][3] - The EXCELERIZE study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of REC-3565 in two parts, focusing on both monotherapy and combination therapies [2][3] Company Overview - Recursion is a clinical stage TechBio company that utilizes AI-driven approaches to enhance drug discovery, operating one of the largest proprietary biological and chemical datasets [4] - The company is headquartered in Salt Lake City and is a founding member of BioHive, a collective for the Utah life sciences industry [5] Market Potential - Approximately 41,000 relapsed and/or refractory patients with chronic lymphocytic leukemia (CLL) and B-cell lymphomas in the U.S. and EU5 are eligible for treatment annually, indicating a significant market opportunity for REC-3565 [3]